ArticleFuture oncology (London, England)2026

Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs.

Evan Y Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.